|
Variable
|
Subgroup 1 (n = 34)
|
Subgroup 2 (n = 40)
|
p value
|
|---|
|
Age (years)
|
43.9 ± 16.3
|
41.9 ± 17.3
|
>0.05
|
|
Male
|
25 (73.5 %)
|
23 (57.5 %)
|
>0.05
|
|
Antecedent infections
|
28 (82.4 %)
|
21 (52.5 %)
|
>0.05
|
|
Cranial nerve involvement
|
26 (76.5 %)
|
24 (60 %)
|
>0.05
|
|
Facial nerve
|
18 (52.9 %)
|
22 (55 %)
|
>0.05
|
|
Glossopharyngeal and vagus nerves
|
18 (52.9 %)
|
12 (30 %)
|
<0.05
|
|
Sensory disturbance
|
16 (47.1 %)
|
17 (42.5 %)
|
>0.05
|
|
Autonomic dysfunction
|
3 (8.8 %)
|
2 (5 %)
|
>0.05
|
|
Pain
|
3 (8.8 %)
|
4 (10 %)
|
>0.05
|
|
Hyporeflexia or areflexia
|
33 (97.1 %)
|
39 (97.5 %)
|
>0.05
|
|
Hospital stay (days)
|
31.0 ± 16.1
|
51.7 ± 31.2
|
<0.05
|
|
Treatment modality
| | |
>0.05
|
|
IVIg
|
18 (52.9 %)
|
15 (37.5 %)
| |
|
IVIg + intravenous corticosteroids
|
11 (32.4 %)
|
18 (45 %)
| |
|
Intravenous corticosteroids
|
2 (5.9 %)
|
4 (10 %)
| |
|
Supportive treatment
|
3 (8.8 %)
|
3 (7.5 %)
| |
-
GBS Guillain-Barré syndrome, IVIg intravenous immunoglobulin, Subgroup 1 mechanically ventilated GBS patients with good short-term prognosis, Subgroup 2 mechanically ventilated GBS patients with poor short-term prognosis
